Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.
Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.
Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.
Phosphagenics Limited
ASX:POH ISIN:AU000000POH7
新闻
2011年2月7日澳洲股市报告包括:Automotive Technology Group (ASX:ATJ)宣布其增压系统的效率为全球最高;煤炭研究显示Aviva Corporation Limited (ASX:AVA)在博茨瓦纳的Mmamantswe项目可生产出口等级的热能煤;EnviroGold Limited (ASX:EVG)加强拉美管理层;Phosphagenics Limited (ASX:POH)宣布在美国合作开发牛皮癣药物。
###
90,353 公司背景浏览
- 本页浏览人次: (过去7日: 14) (过去30日: 48) (自发布以来: 8916)